A comprehensive drug screening panel identifies the presence of various illicit and prescription substances in an individual’s system. This type of assessment analyzes a biological sample, typically urine, to detect specific drugs or their metabolites, indicating recent use. For instance, it can identify opioids, cannabinoids, amphetamines, cocaine, benzodiazepines, barbiturates, phencyclidine (PCP), methadone, propoxyphene, oxycodone, fentanyl, tramadol, and alcohol.
Such an evaluation is crucial in diverse settings, including pre-employment screening, workplace safety programs, clinical toxicology, and monitoring substance abuse treatment. The results provide essential information for making informed decisions regarding hiring, ensuring compliance, diagnosing potential substance use disorders, and verifying adherence to prescribed medication regimens. Historically, the expansion of drug screening panels reflects the evolving landscape of substance use and the increasing need for comprehensive detection methods.